Franz Weidinger

Franz Weidinger

Auto-generated profile, based on publicly available information

Franz Weidinger

Department of Cardiology and Intensive Care Medicine, Landstrasse Clinic , Vienna

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
ATAdam Timmis
Adam Timmis
VAVictor Aboyans
Victor Aboyans
PVPanos Vardas
Panos Vardas
NTNick Townsend
Nick Townsend
ATAleksandra Torbica
Aleksandra Torbica
FWFranz Weidinger
Franz Weidinger
This report from the European Society of Cardiology (ESC) Atlas Project updates and expands upon the 2021 report in presenting cardiovascular disease (CVD) statistics for the ESC member countries. This paper examines inequalities in cardiovascular healthcare and outcomes in ESC member countries utilizing mortality and risk factor data from the World Health Organization and the Global Burden of Disease study with additional economic data from the World Bank. Cardiovascular healthcare data were collected by questionnaire circulated to the national cardiac societies of ESC member countries. Statistics pertaining to 2022, or latest available year, are presented. New material in this report includes contemporary estimates of the economic burden of CVD and mortality statistics for a range of CVD phenotypes. CVD accounts for 11% of the EU’s total healthcare expenditure. It remains the most common cause of death in ESC member countries with over 3 million deaths per year. Proportionately more deaths from CVD occur in middle-income compared with high-income countries in both females (53% vs. 34%) and males (46% vs. 30%). Between 1990 and 2021, median age-standardized mortality rates (ASMRs) for CVD decreased by median >50% in high-income ESC member countries but in middle-income countries the median decrease was <12%. These inequalities between middle- and high-income ESC member countries likely reflect heterogeneous exposures to a range of environmental, socioeconomic, and clinical risk factors. The 2023 survey suggests that treatment factors may also contribute with middle-income countries reporting lower rates per million of percutaneous coronary intervention (1355 vs. 2330), transcatheter aortic valve implantation (4.0 vs. 153.4) and pacemaker implantation (147.0 vs. 831.9) compared with high-income countries. The ESC Atlas 2023 report shows continuing inequalities in the epidemiology and management of CVD between middle-income and high-income ESC member countries. These inequalities are exemplified by the changes in CVD ASMRs during the last 30 years. In the high-income ESC member countries, ASMRs have been in steep decline during this period but in the middle-income countries declines have been very small. There is now an important need for targeted action to reduce the burden of CVD, particularly in those countries where the burden is greatest.

28 May 2020 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Open access
PDF file
GPGuilherme Pessoa-Amorim
Guilherme Pessoa-Amorim
CCChristian F Camm
Christian F Camm
PGParag Gajendragadkar
Parag Gajendragadkar
MTMaria Giovanna Trivieri
Maria Giovanna Trivieri
CACeline Arsac
Celine Arsac
BCBarbara Casadei
Barbara Casadei
Aims: The COVID-19 pandemic required a significant redeployment of worldwide healthcare resources. Fear of infection, national lockdowns and altered healthcare priorities have the potential to impact utilisation of healthcare resources for non-communicable diseases. To survey health professionals’ views of the impact of the COVID-19 pandemic on the rate and timing of admission of patients with ST-elevation myocardial infarction (STEMI), the European Society of Cardiology (ESC) administered an internet-based questionnaire to cardiologists and cardiovascular nurses across 6 continents. Methods and results: 3101 responses were received from 141 countries across 6 continents. 88.3% responded that their country was in “total lockdown” and 7.1% in partial lockdown. 78.8% responded that the number of patients presenting with STEMI was reduced since the coronavirus outbreak and 65.2% indicated that the reduction in STEMI presentations was >40%. Approximately 60% of all respondents reported that STEMI patients presented later than usual and 58.5% that >40% of STEMI patients admitted to hospital presented beyond the optimal window for primary percutaneous intervention (PCI) or thrombolysis. Independent predictors of the reported higher rate of delayed STEMI presentation were a country in total lockdown, >100 COVID-19 cases admitted locally, and the complete restructuring of the local cardiology service. Conclusion: The survey indicates that the impact of COVID-19 on STEMI presentations is likely to be substantial, with both lower presentations and a higher rate of delayed presentations occurring. This has potentially important ramifications for future healthcare and policy planning in the event of further waves of this pandemic.

15 February 2022 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
MLMaddalena Lettino
Maddalena Lettino
JMJulia Mascherbauer
Julia Mascherbauer
MNMatias Nordaby
Matias Nordaby
AZAndré Ziegler
André Ziegler
JCJean Philippe Collet
Jean Philippe Collet
IRIsabelle Richard-Lordereau
Isabelle Richard-Lordereau
The growing elderly population worldwide represents a major challenge for caregivers, healthcare providers, and society. Older patients have a higher prevalence of cardiovascular (CV) disease, high rates of CV risk factors, and multiple age-related comorbidities. Although prevention and management strategies have been shown to be effective in older people, they continue to be under-used, and under-studied. In addition to hard endpoints, frailty, cognitive impairments, and patients’ re-assessment of important outcomes (e.g. quality of life vs. longevity) are important aspects for older patients and emphasize the need to include a substantial proportion of older patients in CV clinical trials. To complement the often skewed age distribution in clinical trials, greater emphasis should be placed on real-world studies to assess longer-term outcomes, especially safety and quality of life outcomes. In the complex environment of the older patient, a multidisciplinary care team approach with the involvement of the individual patient in the decision-making process can help optimize prevention and management strategies. This article aims to demonstrate the growing burden of ageing in real life and illustrates the need to continue primary prevention to address CV risk factors. It summarizes factors to consider when choosing pharmacological and interventional treatments for the elderly and the need to consider quality of life and patient priorities when making decisions.

13 January 2011 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
TBTimm Bauer
Timm Bauer
HMHelge Mollmann
Helge Mollmann
FWFranz Weidinger
Franz Weidinger
UZUwe Zeymer
Uwe Zeymer
RSRicardo Seabra‐Gomes
Ricardo Seabra‐Gomes
AGAnselm K. Gitt
Anselm K. Gitt

16 December 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
LBLouise Bowman
Louise Bowman
FWFranz Weidinger
Franz Weidinger
MAMichelle A Albert
Michelle A Albert
EFEdward T A Fry
Edward T A Fry
FPFAUSTO J PINTO
FAUSTO J PINTO
Randomized controlled trials are the cornerstone for reliably evaluating therapeutic strategies.1 However, during the past 25 years, the rules and regulations governing randomized trials and their interpretation have become increasingly burdensome,2 and the cost and complexity of trials has become prohibitive.3 The present model is unsustainable, and the development of potentially effective treatments is often stopped prematurely on financial grounds, while existing drug treatments or non-drug interventions (such as screening strategies or management tools) may not be assessed reliably. The current ‘best regulatory practice’ environment, and a lack of consensus on what that requires, too often makes it unduly difficult to undertake efficient randomized trials able to provide reliable evidence about the safety and efficacy of potentially valuable interventions. Inclusion of underrepresented population groups and lack of diversity also remain among the challenges.

1 April 2002 in European Surgery
Verified
Journal Article
Closed access
PDF file
JDJózef Dulak
Józef Dulak
LPL. Partyka
L. Partyka
AJAlicja Józkowicz
Alicja Józkowicz
GHG. Heba
G. Heba
MPM. Prager
M. Prager
IHI. Huk
I. Huk